FRANCE TAVI注册研究:抗凝治疗与TAVR后长期死亡率及早期瓣膜功能障碍的关系
基于法国FRANCE TAVI前瞻性多中心注册研究,分析11,469例出院存活且抗凝信息已知的TAVR患者长期全因死亡,以及2,555例有至少两次超声评估患者的早期生物瓣功能障碍(BVD)。中位随访约495天,男性、房颤史和慢性肾衰竭是全因死亡最强独立相关因素;出院抗凝(主要为房颤)与较低BVD风险独立相关,而慢性肾衰竭和瓣膜尺寸≤23 mm与较高BVD风险相关。
要点
- 男性、房颤史和慢性肾衰竭是TAVR后长期全因死亡的独立相关因素。
- 出院抗凝与较低早期生物瓣功能障碍风险独立相关(aOR 0.54)。
- 瓣膜尺寸≤23 mm和慢性肾衰竭与较高早期BVD风险独立相关。
核心结论
- 性别、肾衰竭和房颤对TAVR后约3年随访的死亡影响最大,而抗凝(多为房颤适应)降低TAVR后BVD风险。
研究设计与样本
- FRANCE TAVI为法国前瞻性、多中心、全国性注册研究,纳入2013年1月1日至2015年12月31日12,804例患者,其中11,469例出院存活且抗凝治疗已知者纳入死亡分析,2,555例有至少两次超声评估者纳入BVD评估。
- 采用多重插补处理缺失值,全因死亡用逐步多变量Cox回归,BVD用逻辑回归,并进行了仅保留完整数据患者的敏感性分析。
主要发现
- 死亡分析人群平均±SE年龄82.8±0.07岁,logistic EuroSCORE 17.8±0.1%,平均随访495±3.5天。
- 男性(aHR 1.63;95%CI 1.44–1.84;p<0.001)、房颤史(aHR 1.41;95%CI 1.23–1.62;p<0.001)和慢性肾衰竭(aHR 1.37;95%CI 1.23–1.53;p<0.001)是全因死亡最强独立相关因素;阿司匹林或氯吡格雷与死亡无独立关联。
- 出院抗凝(aOR 0.54;95%CI 0.35–0.82;p=0.005)和非股动脉入路(aOR 0.53;95%CI 0.28–1.02;p=0.049)与较低BVD风险独立相关。
- 慢性肾衰竭(aOR 1.46;95%CI 1.03–2.08;p=0.034)和瓣膜尺寸≤23 mm(aOR 3.43;95%CI 2.41–4.89;p<0.001)与较高BVD风险独立相关。
- 约三分之一患者有房颤史,同等比例出院时使用口服抗凝药(n=3,836)。
临床怎么用
- TAVR后评估死亡风险时应关注男性、房颤史和慢性肾衰竭。
- 对房颤等有抗凝指征者,出院抗凝可能有助于降低早期生物瓣功能障碍风险。
- 小尺寸瓣膜(≤23 mm)和慢性肾衰竭患者需加强超声随访以监测BVD。
局限性
- BVD评估仅限有至少两次超声评估的2,555例患者,可能存在选择偏倚。
- 抗凝治疗非随机分配,残留混杂可能影响因果推断。
- 早期BVD定义基于超声梯度变化,未涵盖其他类型瓣膜功能障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal antithrombotic treatment after transcatheter aortic valve replacement (TAVR) remains a matter of debate. Although dual antiplatelet therapy is recommended, single antiplatelet therapy or oral anticoagulation is frequently used according to the patient profile. Whether this approach may affect clinical outcome is unknown. OBJECTIVES: FRANCE TAVI (French Transcatheter Aortic Valve Implantation) is a prospective, multicenter, nationwide French registry. The study objectives were to identify independent correlates of long-term all-cause mortality and early bioprosthetic valve dysfunction (BVD), defined as increased prosthetic gradient ≥10 mm Hg or new gradient ≥20 mm Hg. METHODS: To account for missing values, multiple imputations were performed. Stepwise multivariable Cox regression and logistic regression were used for all-cause mortality and bioprosthesis valve dysfunction was used, respectively. Sensitivity analysis retaining only patients with complete data were also performed. RESULTS: Of 12,804 patients included in the registry between January 1, 2013, and December 31, 2015, a total of 11,469 (mean ± SE age: 82.8 ± 0.07 years; logistic European System for Cardiac Operative Risk Evaluation: 17.8 ± 0.1%; mean duration of follow-up: 495 ± 3.5 days) were alive at discharge with known antithrombotic treatment and were analyzed for mortality. A total of 2,555 patients had at least 2 echocardiographic evaluations and were eligible for BVD assessment. One-third of patients had a history of atrial fibrillation, and the same proportion had oral anticoagulation at discharge (n = 3,836). Neither aspirin nor clopidogrel was independently associated with mortality. Male sex (adjusted hazard ratio [aHR]: 1.63; 95% confidence interval [CI]: 1.44 to 1.84; p < 0.001), history of atrial fibrillation (aHR: 1.41; 95% CI: 1.23 to 1.62; p < 0.001), and chronic renal failure (aHR: 1.37; 95% CI: 1.23 to 1.53; p < 0.001) were the strongest independent correlates of mortality. Anticoagulation at discharge (adjusted odds ratio [aOR]: 0.54; 95% CI: 0.35 to 0.82; p = 0.005) and a nonfemoral approach (aOR: 0.53; 95% CI: 0.28 to 1.02; p = 0.049) were independently associated with lower rates of BVD, whereas chronic renal failure (aOR: 1.46; 95% CI: 1.03 to 2.08; p = 0.034) and prosthesis size ≤23 mm (aOR: 3.43; 95% CI: 2.41 to 4.89; p < 0.001) yielded higher risk of BVD. CONCLUSIONS: Sex, renal failure, and atrial fibrillation affected mortality the most at the 3-year follow-up. In contrast, anticoagulation (mostly given for atrial fibrillation) decreased the risk of BVD after TAVR.
引用
- Overtchouk P, Guedeney P, Rouanet S, et al. Long-Term Mortality and Early Valve Dysfunction According to Anticoagulation Use: The FRANCE TAVI Registry. J Am Coll Cardiol. 2018. PMID: 30153483. doi:10.1016/j.jacc.2018.08.1045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。